健康な被験者および過体重肥満の被験者における LAE102 の評価
健康な被験者および過体重/肥満の被験者における LAE102 の安全性、忍容性、および薬物動態を評価するための、無作為化、二重盲検、プラセボ対照、単回および複数回用量漸増第 I 相試験
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of LAE102 injection in healthy and overweight/obese participants, and also evaluate the preliminary pharmacodynamic effect of multiple dose injections in overweight/obese participants.
調査の概要
状態
詳細な説明
Part A is a randomized, double-blinded, placebo-controlled, single ascending dose by Intravenous (IV) administration in 40 Healthy participants;
Part B is a randomized, double-blinded, placebo-controlled, single ascending dose by subcutaneous (SC) administration in 24 Healthy participants;
Part C is a randomized, double-blind, placebo-controlled, multiple dose ascending and expanding by subcutaneous (SC) administration in 60 overweight/obese participants.
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国、201203
- Fudan Zhongshan Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Male or female and aged 18 to 65 years (inclusive) at the screening visit
- Male Body weight ≥ 50 kg, female Body weight ≥ 45 kg. For Part A&B, 18.5 ≤ BMI ≤ 28 kg/m². For part C, 26.0 ≤ BMI ≤ 40.0 kg/m²
- Negative for human immunodeficiency virus antibody (HIV-Ab).
- Female subjects with no childbearing potential or with childbearing potential which serum human chorionic gonadotropin (hCG) test must <5mIU/mL .
- Male subjects are not allowed to donate sperm during this trial.
- Voluntarily participate in the study and provide a signed and dated informed consent form.
- Willing to comply with the scheduled visits, study treatment, laboratory tests, and other study-related procedures and requirements as stipulated in the study protocol.
Exclusion Criteria:
- With clinically significant abnormalities in vital signs, physical examination, ECG or laboratory test results specified in the protocol.
- Allergy to the investigational drug or its excipients, or a history of severe allergy (including any food or drug allergies).
- Self-reported weight change is more than 5% in the previous 3 months prior to screening.
- Diagnosed with secondary overweight or obesity.
- Any clinically significant medical conditions and any diseases affecting the safety of the subject or the determination of study results.
- History of major diseases or physical conditions in the central nervous system, respiratory system, cardiovascular system, digestive system, blood system, endocrine system, musculoskeletal diseases, mental illness, urinary system, or tumors, or any existing acute diseases, or other diseases or physical conditions that may affect the study or pose an unacceptable risk to the subjects.
- Positive for hepatitis B surface antigen (HBsAg), or hepatitis C antibody (HCV-Ab), or syphilis spirochete antibody (TP-Ab).
- Known or suspected history of substance abuse or positive drug screening test.
- Alcohol abuse within 1 year before screening or positive alcohol breath test at baseline.
- Smoking more than 5 cigarettes per day within 3 months before screening, or unable to comply with the prohibition of smoking during the study period.
- Received any vaccine within 30 days prior to screening, or planned to receive any vaccine during the study period.
- Inability to ensure no use of any drugs, including prescription and non-prescription drugs (excluding paracetamol, ibuprofen, and topically applied eye/nasal drops and ointments with no systemic exposure risk), vitamins, supplements and herbal medicines, from 14 days before the initial administration (if the half-life of the drug used exceeds 14 days, then 5 half-lives shall apply) until the last visit period.
- Participated in any clinical trial and received an investigational medicine or medical device within 3 months prior to dosing of the investigational product.
- Underwent major surgery within 30 days before the initial administration or planned to undergo major surgery during the study period.
- Donated blood or experienced blood loss ≥400 mL within 3 months before screening or received a blood transfusion.
- Have special dietary requirements and cannot comply with a standardized diet.
- History of fainting or syncope.
- Dieting or receiving weight loss treatment within 30 days before the initial administration or experiencing major changes in lifestyle.
- Use of GLP-1 receptor agonists, or weight loss medications or systemic corticosteroids (oral or intravenous for more than 7 days), or psychiatric medications within 3 months prior to the initial administration. Applicable to part C.
- Regular engaged in muscle strength related exercise, applicable to part C.
- Other situation that the investigator considers not appropriate.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:順次割り当て
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Part A LAE102 IV
Single dose LAE102 by IV administration |
A single dose of LAE102 administered intravenously
他の名前:
|
|
プラセボコンパレーター:Part A placebo IV
Single dose placebo by IV administration |
A single dose of placebo administered intravenously
他の名前:
|
|
実験的:Part B LAE102 SC
Single dose LAE102 by SC administration |
Single dose of LAE102 administered subcutaneously
他の名前:
|
|
プラセボコンパレーター:Part B placebo SC
Single dose placebo by SC administration |
single dose of placebo administered subcutaneously
他の名前:
|
|
実験的:Part C LAE102 SC
Multiple dose LAE102 by SC administration |
Multiple dose of LAE102 administered subcutaneously
他の名前:
|
|
プラセボコンパレーター:Part C placebo SC
Multiple dose placebo by SC administration |
Multiple dose of placebo administered subcutaneously
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number & severity of participants with treatment-related adverse events as assessed by CTCAE V5.0
時間枠:From Day 1 to Day 29 for single dose part. From Day 1 to Day 196 for multiple dose part
|
Findings on physical examination, ECG, vital signs, and reports of the laboratory results based on the CTCAE v5.0 |
From Day 1 to Day 29 for single dose part. From Day 1 to Day 196 for multiple dose part
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
characterize the peak of serum concentration (Cmax) of LAE102 injection in healthy subjects
時間枠:From pre-dose to Day 29 for single dose part. From pre-dose to Day 196 for multiple dose part.
|
For both intravenously guttae & subcutaneous injection, to evaluate the maximum observed serum concentration(Cmax) |
From pre-dose to Day 29 for single dose part. From pre-dose to Day 196 for multiple dose part.
|
|
characterize the area under the serum concentration versus time curve (AUC) of LAE102 injection in healthy subjects
時間枠:From pre-dose to Day 29 for single dose part. From pre-dose to Day 196 for multiple dose part.
|
For both intravenously guttae & subcutaneous injection, to evaluate the area under the serum concentration versus time curve (AUC) |
From pre-dose to Day 29 for single dose part. From pre-dose to Day 196 for multiple dose part.
|
|
evaluate the expression levels of Activin A in blood samples
時間枠:From pre-dose to Day 29 for single dose part. From pre-dose to Day 196 for multiple dose part.
|
The validated methodology was employed to assay serum levels of Activin A in biological samples. |
From pre-dose to Day 29 for single dose part. From pre-dose to Day 196 for multiple dose part.
|
|
Incidence of positive Anti-drug antibody(ADA) after administration
時間枠:pre-dose to Day 29 for single dose part. From pre-dose to Day 196 for multiple dose part.
|
Test ADA status in biological sample via validated methodology |
pre-dose to Day 29 for single dose part. From pre-dose to Day 196 for multiple dose part.
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Preliminary pharmacodynamic of total body weight for multiple dose part
時間枠:From pre-dose to Day 168.
|
Changes and percentage changes in total body weight (kg) after administration |
From pre-dose to Day 168.
|
|
Preliminary pharmacodynamic of lean mass for multiple dose part
時間枠:From pre-dose to Day 168.
|
Changes and percentage changes in lean mass after administration |
From pre-dose to Day 168.
|
|
Preliminary pharmacodynamic of fat mass for multiple dose part
時間枠:From pre-dose to Day 168.
|
Changes and percentage changes in fat mass after administration |
From pre-dose to Day 168.
|
|
Preliminary pharmacodynamic of thigh muscle volume for multiple dose part
時間枠:From pre-dose to Day 168
|
Changes and percentage changes in thigh muscle volume after administration |
From pre-dose to Day 168
|
|
Preliminary pharmacodynamic of bone mineral density(BMD) for multiple dose part
時間枠:From pre-dose to Day 168
|
Changes and percentage changes in BMD after administration |
From pre-dose to Day 168
|
|
BMI/waist circumference change and percentage.
時間枠:From pre-dose to Day 29 forsingle dose. From pre-dose to Day 196 for multiple dose.
|
Assess the Body Mass Index (BMI)/waist circumference change and percentage. |
From pre-dose to Day 29 forsingle dose. From pre-dose to Day 196 for multiple dose.
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Xuening Li, Professor、Zhongshan hospital affiliated to Fundan University
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。